Celon Pharma S.A. received a positive assessment and funding recommendation from the National Centre for Research and Development (NCBiR) for 3 projects of developing innovative medicinal products

The applications where subject to a full, two-stage expert assessment and were selected from among a total of 23 submitted projects applying for co-funding from the InnoNeuroPharm programme.
Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:  Sector-specific programmes are very important tools for supporting research and development activity in the entire industry in Poland. The high grade given to the applications we submitted is the result of our entire research team’s hard work. We are now waiting for a technical verification, after which an agreement will be concluded with the National Centre for Research and Development. These are very important innovative projects which will add on our current portfolio. They provide for a pre-clinical validation of drug candidates as well as their clinical development at various phases. We are facing ambitious goals and a period of very intensive work. We are ready for this.
A total of 23 applications for co-funding for the total amount of PLN 213,386,996.40 were submitted for the first edition. After the expert assessment, 13 projects received a positive grade and will be qualified for co-funding.
More information can be found at the website of the National Centre for Research and Development